Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-20507 with pegylated interferon alfa in chronic hepatitis B
NCT07135349Phase 2Active, not recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of BW-20507 in Chronic Hepatitis B (CHB), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd.. Started Sep 2025; status: active, not recruiting.
02
Drugs
BW-20507
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07135349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135349.